A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

A Single-Dose, Double-Blind, Placebo-Controlled, Randomized, Crossover Study to Determine the Abuse Potential of Single Oral Dose of Seltorexant Compared To Suvorexant and Zolpidem

The purpose of this study is to evaluate the abuse potential of seltorexant compared to placebo and two active comparators (zolpidem and suvorexant) in non-dependent, recreational sedative users.

Study Overview

• Status: Completed
• Conditions: Healthy Non-dependent, Recreational Sedative Users; Abuse Potential
• Intervention / Treatment: Drug: Suvorexant; Drug: Zolpidem; Drug: Placebo; Drug: Seltorexant

• Study Type: Interventional
• Enrollment (Actual): 127
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Kansas
    • Overland Park, Kansas, United States, 66212
      • Altasciences Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Be a current, recreational, not physically dependent, drug user
• Participant must be medically stable
• All female participants must have a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening and a negative urine pregnancy test on Day -1 of the qualification phase and on Day -1 of each treatment period of the treatment Phase
• Blood pressure (after the participant is in a sitting position for 5 minutes) between 90 millimeters of mercury (mmHg) and 160 mmHg systolic, inclusive, and no higher than 100 mmHg diastolic at screening and Day -1 prior to qualification phase randomization
• A 12-lead ECG consistent with normal cardiac conduction and function, including: sinus rhythm, pulse rate between 40 and 100 beats per minute (bpm), QTc interval less than or equal to (<=) 450 milliseconds (ms) for males, <=470 for females, QRS interval of less than (<) 120 ms, PR interval <210 ms, Morphology consistent with healthy cardiac conduction and function

Exclusion Criteria:

• Known allergies to seltorexant, zolpidem, and suvorexant
• Previous history of recurrent fainting, collapses, syncope, orthostatic hypotension, or vasovagal reactions
• Prescription medications except for stable medical problems such as hypertension, elevated cholesterol, and non-insulin-dependent diabetes mellitus with stable medications for at least 1 month prior to screening
• Participants who have ever been in treatment for substance use disorders (except smoking cessation) or are currently seeking treatment for substance use disorders. In addition, currently seeking or participating in a substance rehabilitation program should be excluded
• Preplanned surgery or procedures that would interfere with the conduct of the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

12

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Qualification Phase: Treatment Sequence YXZ; Participants will receive a single oral dose of suvorexant (Treatment Y) in qualification period 1, followed by single oral dose of placebo (Treatment X) in qualification period 2 and then single oral dose of zolpidem (Treatment Z) in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.	Drug: Suvorexant; Suvorexant will be administered orally as per assigned treatment sequence.; Drug: Zolpidem; Zolpidem will be administered orally as per assigned treatment sequence.; Drug: Placebo; Placebo will be administered orally as per assigned treatment sequence.
Experimental: Qualification Phase: Treatment Sequence ZYX; Participants will receive Treatment Z in qualification period 1, followed by Treatment Y in qualification period 2, and then Treatment X in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.	Drug: Suvorexant; Suvorexant will be administered orally as per assigned treatment sequence.; Drug: Zolpidem; Zolpidem will be administered orally as per assigned treatment sequence.; Drug: Placebo; Placebo will be administered orally as per assigned treatment sequence.
Experimental: Qualification Phase: Treatment Sequence XZY; Participants will receive Treatment X in qualification period 1, followed by Treatment Z in qualification period 2, and then Treatment Y in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.	Drug: Suvorexant; Suvorexant will be administered orally as per assigned treatment sequence.; Drug: Zolpidem; Zolpidem will be administered orally as per assigned treatment sequence.; Drug: Placebo; Placebo will be administered orally as per assigned treatment sequence.
Experimental: Qualification Phase: Treatment Sequence YZX; Participants will receive Treatment Y in qualification period 1, followed by Treatment Z in qualification period 2, and then Treatment X in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.	Drug: Suvorexant; Suvorexant will be administered orally as per assigned treatment sequence.; Drug: Zolpidem; Zolpidem will be administered orally as per assigned treatment sequence.; Drug: Placebo; Placebo will be administered orally as per assigned treatment sequence.
Experimental: Qualification Phase: Treatment Sequence ZXY; Participants will receive Treatment Z in qualification period 1, followed by Treatment X in qualification period 2, and then Treatment Y in qualification period 3 on Day 1 during qualification phase. Each treatment will be separated by washout of at least 3 days.	Drug: Suvorexant; Suvorexant will be administered orally as per assigned treatment sequence.; Drug: Zolpidem; Zolpidem will be administered orally as per assigned treatment sequence.; Drug: Placebo; Placebo will be administered orally as per assigned treatment sequence.
Experimental: Qualification Phase: Treatment Sequence XYZ; Participants will receive Treatment X in qualification period 1, followed by Treatment Y in qualification period 2, and then Treatment Z in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.	Drug: Suvorexant; Suvorexant will be administered orally as per assigned treatment sequence.; Drug: Zolpidem; Zolpidem will be administered orally as per assigned treatment sequence.; Drug: Placebo; Placebo will be administered orally as per assigned treatment sequence.
Experimental: Treatment Phase: Treatment Sequence ABFCED; Participants will receive a single oral dose of placebo (Treatment A) in treatment period 1, followed by single oral dose of suvorexant (Treatment B) in treatment period 2, single oral Dose 3 of seltorexant (Treatment F) in treatment period 3, single oral dose of zolpidem (Treatment C) in treatment period 4, single oral Dose 2 of seltorexant (Treatment E) in treatment period 5 and then a single oral Dose 1 of seltorexant (Treatment D) in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.	Drug: Suvorexant; Suvorexant will be administered orally as per assigned treatment sequence.; Drug: Zolpidem; Zolpidem will be administered orally as per assigned treatment sequence.; Drug: Placebo; Placebo will be administered orally as per assigned treatment sequence.; Drug: Seltorexant; Seltorexant will be administered orally as per assigned treatment sequence.; Other Names: JNJ-42847922
Experimental: Treatment Phase: Treatment Sequence BCADFE; Participants will receive Treatment B in treatment period 1, followed by Treatment C in treatment period 2, Treatment A in treatment period 3, Treatment D in treatment period 4, Treatment F in treatment period 5 and then Treatment E in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.	Drug: Suvorexant; Suvorexant will be administered orally as per assigned treatment sequence.; Drug: Zolpidem; Zolpidem will be administered orally as per assigned treatment sequence.; Drug: Placebo; Placebo will be administered orally as per assigned treatment sequence.; Drug: Seltorexant; Seltorexant will be administered orally as per assigned treatment sequence.; Other Names: JNJ-42847922
Experimental: Treatment Phase: Treatment Sequence CDBEAF; Participants will receive Treatment C in treatment period 1, followed by Treatment D in treatment period 2, Treatment B in treatment period 3, Treatment E in treatment period 4, Treatment A in treatment period 5 and then Treatment F in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.	Drug: Suvorexant; Suvorexant will be administered orally as per assigned treatment sequence.; Drug: Zolpidem; Zolpidem will be administered orally as per assigned treatment sequence.; Drug: Placebo; Placebo will be administered orally as per assigned treatment sequence.; Drug: Seltorexant; Seltorexant will be administered orally as per assigned treatment sequence.; Other Names: JNJ-42847922
Experimental: Treatment Phase: Treatment Sequence DECFBA; Participants will receive Treatment D in treatment period 1, followed by Treatment E in treatment period 2, Treatment C in treatment period 3, Treatment F in treatment period 4, Treatment B in treatment period 5 and then Treatment A in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.	Drug: Suvorexant; Suvorexant will be administered orally as per assigned treatment sequence.; Drug: Zolpidem; Zolpidem will be administered orally as per assigned treatment sequence.; Drug: Placebo; Placebo will be administered orally as per assigned treatment sequence.; Drug: Seltorexant; Seltorexant will be administered orally as per assigned treatment sequence.; Other Names: JNJ-42847922
Experimental: Treatment Phase: Treatment Sequence: EFDACB; Participants will receive Treatment E in treatment period 1, followed by Treatment F in treatment period 2, Treatment D in treatment period 3, Treatment A in treatment period 4, Treatment C in treatment period 5 and then Treatment B in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.	Drug: Suvorexant; Suvorexant will be administered orally as per assigned treatment sequence.; Drug: Zolpidem; Zolpidem will be administered orally as per assigned treatment sequence.; Drug: Placebo; Placebo will be administered orally as per assigned treatment sequence.; Drug: Seltorexant; Seltorexant will be administered orally as per assigned treatment sequence.; Other Names: JNJ-42847922
Experimental: Treatment Phase: Treatment Sequence FAEBDC; Participants will receive Treatment F in treatment period 1, followed by Treatment A in treatment period 2, Treatment E in treatment period 3, Treatment B in treatment period 4, Treatment D in treatment period 5 and Treatment C in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.	Drug: Suvorexant; Suvorexant will be administered orally as per assigned treatment sequence.; Drug: Zolpidem; Zolpidem will be administered orally as per assigned treatment sequence.; Drug: Placebo; Placebo will be administered orally as per assigned treatment sequence.; Drug: Seltorexant; Seltorexant will be administered orally as per assigned treatment sequence.; Other Names: JNJ-42847922

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Peak Maximum Effect (Emax) for Drug Liking (At this Moment) Visual Analog Scale (VAS)	Emax for drug liking VAS will be reported. Drug liking VAS is a bipolar scale designed to assess a participant's liking for a given study intervention at the time the question is being asked (that is, at this moment). It is scored as an integer ranging from 0 (strong disliking) to 100 (strong liking).	Up to 24 hour post-dose (up to Day 2)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Drug Liking VAS (Emax)	Emax for overall drug liking VAS will be reported. Peak effect for overall drug liking based on bipolar VAS from 0 (strong disliking) to 100 (strong liking).	12 hour and 24 hour post-dose
Take Drug Again VAS (Emax)	Emax for take drug again VAS will be reported. Peak effect for take drug again based on bipolar VAS from 0 (definitely no) to 100 (definitely so).	12 hour and 24 hour post-dose
Subjective Drug Value (Emax)	Subjective drug value will be reported. The subjective drug value is a proxy measure of reinforcing efficacy that involves a series of independent, theoretical forced choices between drug administered and different monetary values.	12 hour and 24 hour post-dose
High VAS (Emax)	High VAS is one of the measures of positive effects that assesses the effect experienced by the participant on a 100 millimeter (mm) unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= definitely not) to 'extremely' (score of 100 = definitely so).	Pre-dose up to 24 hours post-dose (up to Day 2)
Time to Peak Effect (TEmax) for Drug Liking (At this Moment) VAS	TEmax is defined as time to peak effect for drug liking (at this moment). Drug liking VAS is a bipolar scale designed to assess a participant's liking for a given study intervention at the time the question is being asked (that is, at this moment). It is scored as an integer ranging from 0 (strong disliking) to 100 (strong liking).	Up to 24 hour post-dose (up to Day 2)
Minimum Effect (Emin) for Drug Liking (At this Moment) VAS	Emin is defined as minimum effect for drug liking (at this moment). Drug liking VAS is a bipolar scale designed to assess a participant's liking for a given study intervention at the time the question is being asked (that is, at this moment). It is scored as an integer ranging from 0 (strong disliking) to 100 (strong liking).	Up to 24 hour post-dose (up to Day 2)
Time to Minimum Effect (TEmin) for Drug Liking (At this Moment) VAS	TEmin is defined as time to minimum effect for drug liking (at this moment). Drug liking VAS is a bipolar scale designed to assess a participant's liking for a given study intervention at the time the question is being asked (that is, at this moment). It is scored as an integer ranging from 0 (strong disliking) to 100 (strong liking).	Up to 24 hour post-dose (up to Day 2)
Time-averaged Area Under the Effects Curve (TA_AUE) for Drug Liking (At This Moment) VAS	TA_AUE is defined as time-averaged area under the effects curve for drug liking (at this moment). Drug liking VAS is a bipolar scale designed to assess a participant's liking for a given study intervention at the time the question is being asked (that is, at this moment). It is scored as an integer ranging from 0 (strong disliking) to 100 (strong liking).	Up to 24 hour post-dose (up to Day 2)
TEmax of High VAS	TEmax of high VAS will be reported. High VAS is one of the measures of positive effects that assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= definitely not) to 'extremely' (score of 100 = definitely so).	Pre-dose up to 24 hours post-dose (up to Day 2)
TA_AUE of High VAS	TA_AUE of high VAS will be reported. High VAS is one of the measures of positive effects that assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= definitely not) to 'extremely' (score of 100 = definitely so).	Pre-dose up to 24 hours post-dose (up to Day 2)
Emax of Good Effect VAS	Emax of good effect VAS will be reported. Good drug effects VAS is one of the measures of positive effects that assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= definitely not) to 'extremely' (score of 100 mm= definitely so).	Up to 24 hour post-dose (up to Day 2)
TEmax of Good Effects VAS	TEmax of good effects VAS will be reported. Good drug effects VAS is one of the measures of positive effects that assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= definitely not) to 'extremely' (score of 100 mm= definitely so).	Up to 24 hour post-dose (up to Day 2)
TA_AUE of Good Effects VAS	TA_AUE of good effects VAS will be reported. Good drug effects VAS is one of the measures of positive effects that assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= definitely not) to 'extremely' (score of 100 mm= definitely so).	Up to 24 hour post-dose (up to Day 2)
Emax of Bad Effects VAS	Emax of bad effects VAS will be reported. Bad effects VAS measures the negative effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so').	Up to 24 hour post-dose (up to Day 2)
TA_AUE of Bad Effects VAS	TA_AUE for bad effects VAS will be reported. Bad effects VAS measures the negative effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so').	Up to 24 hour post-dose (up to Day 2)
TEmax of Bad Effects VAS	TEmax of bad effects VAS will be reported. Bad effects VAS measures the negative effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so').	Up to 24 hour post-dose (up to Day 2)
Emin of Drowsiness/Alertness VAS	Emin of Drowsiness/Alertness VAS will be reported. Alertness/Drowsiness VAS measures the sedative effects. It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of 'neither drowsy nor alert' (score of 50 mm), on the left with 'very drowsy' (score of 0 mm) and on the right with 'very alert' (score of 100 mm).	Pre-dose up to 24 hours post-dose (up to Day 2)
TEmin of Drowsiness/Alertness VAS	TEmin of Drowsiness/Alertness VAS will be reported. Alertness/Drowsiness VAS measures the sedative effects. It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of 'neither drowsy nor alert' (score of 50 mm), on the left with 'very drowsy' (score of 0 mm) and on the right with 'very alert' (score of 100 mm).	Pre-dose up to 24 hours post-dose (up to Day 2)
Time-averaged Area Over the Effect Time Curve (TA_AOE) of Drowsiness/Alertness VAS	TA_AOE is defined as time-averaged area over the effect time curve. Alertness/Drowsiness VAS measures the sedative effects. It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of 'neither drowsy nor alert' (score of 50 mm), on the left with 'very drowsy' (score of 0 mm) and on the right with 'very alert' (score of 100 mm).	Pre-dose up to 24 hours post-dose (up to Day 2)
Emin of Relaxation/Agitation VAS	Emin of relaxation/agitation VAS will be reported. Agitation/Relaxation VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm).	Pre-dose up to 24 hours post-dose (up to Day 2)
TEmin of Relaxation/Agitation VAS	TEmin of relaxation/agitation VAS will be reported. Agitation/Relaxation VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm).	Pre-dose up to 24 hours post-dose (up to Day 2)
TA_AOE of Relaxation/Agitation VAS	TA_AOE of relaxation/agitation VAS will be reported. Agitation/Relaxation VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm).	Pre-dose up to 24 hours post-dose (up to Day 2)
TEmax of Dizziness VAS	TEmax of dizziness VAS will be reported. Dizziness VAS assesses the effect of dizziness by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm).	Pre-dose up to 24 hour post-dose (up to Day 2)
Emax of Dizziness VAS	Emax of dizziness VAS will be reported. Dizziness VAS assesses the effect of dizziness by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm).	Pre-dose up to 24 hour post-dose (up to Day 2)
TA_AUE of Dizziness VAS	TA_AUE of dizziness VAS will be reported. Dizziness VAS assesses the effect of dizziness by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm).	Pre-dose up to 24 hour post-dose (up to Day 2)
Emax of Any Effects VAS	Emax of any effects VAS will be reported. Any drug effects VAS measures other subjective effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so').	Up to 24 hour post-dose (up to Day 2)
TEmax of Any Effects VAS	TEmax of any effects VAS will be reported. Any drug effects VAS measures other subjective effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so').	Up to 24 hour post-dose (up to Day 2)
TA_AUE of Any Effects VAS	TA_AUE of any effects VAS will be reported. Any drug effects VAS measures other subjective effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so').	Up to 24 hour post-dose (up to Day 2)
Drug Similarity VAS	Drug similarity VAS will be reported. The Drug Similarity unipolar VAS items provide an estimate of the drug class with which drug users identify the test drug. It is a unipolar scale ranging from 0 (not at all similar) to 100 points ( very similar).	24 hour post-dose
Percentage of Participants with Adverse Events (AEs)	An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.	Up to Week 20
Percentage of Participants with Serious Adverse Events (SAEs)	An SAE is defined as any untoward medical occurrence that: results in death, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event.	Up to Week 20
Percentage of Participants with Abnormalities in Clinical Laboratory Parameters	Percentage of participants with abnormalities in clinical laboratory parameters (included hematology, clinical chemistry, and routine urinalysis) will be reported.	Up to 24 hour post-dose (up to Day 2)
Percentage of Participants with Abnormalities in Vital Signs	Percentage of participants with abnormalities in vital signs (included temperature, pulse/heart rate, blood pressure [diastolic and systolic]) will be reported.	Up to 24 hour post-dose (up to Day 2)
Emin of Modified Observer's Assessment of Alertness/Sedation (MOAA/S) of Composite and Sum Score	Emin of MOAA/S of composite and sum score will be reported. The MOAA/S is an observer-rated measure of alertness/sedation that is used widely in clinical research. The MOAA/S scores range from 5 (not sedated) to 0 (unarousable). The observer's assessment of alertness/sedation scale (OAA/S) was developed to measure the level of alertness in participants who are sedated. The OAA/S is a reliable validated measure and was shown to be sensitive to different levels of sedation and is composed of 4 assessment categories that include responsiveness, speech, facial expression, and eyes. The MOAA/S includes only the Responsiveness assessment category.	Up to 24 hour post-dose (up to Day 2)
TA_AOE of MOAA/S of composite and sum score	TA_AOE of MOAA/S of composite and sum score will be reported. The MOAA/S is an observer-rated measure of alertness/sedation that is used widely in clinical research. The MOAA/S scores range from 5 (not sedated) to 0 (unarousable). The observer's assessment of alertness/sedation scale (OAA/S) was developed to measure the level of alertness in participants who are sedated. The OAA/S is a reliable validated measure and was shown to be sensitive to different levels of sedation and is composed of 4 assessment categories that include responsiveness, speech, facial expression, and eyes. The MOAA/S includes only the Responsiveness assessment category.	Up to 24 hour post-dose (up to Day 2)

Collaborators and Investigators

• Sponsor: Janssen Research & Development, LLC
• Investigators: Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Study record dates

Study Major Dates

• Study Start (Actual): December 17, 2021
• Primary Completion (Actual): May 12, 2023
• Study Completion (Actual): May 12, 2023

Study Registration Dates

• First Submitted: October 21, 2021
• First Submitted That Met QC Criteria: November 2, 2021
• First Posted (Actual): November 3, 2021

Study Record Updates

• Last Update Posted (Actual): July 21, 2023
• Last Update Submitted That Met QC Criteria: July 20, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Hypnotics and Sedatives; GABA Agents; Sleep Aids, Pharmaceutical; Orexin Receptor Antagonists; GABA-A Receptor Agonists; GABA Agonists; Suvorexant; Zolpidem
• Other Study ID Numbers: CR109099; 42847922MDD1017 (Other Identifier: Janssen Research & Development, LLC)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No